Authors
Akira Endo, Kazuma Yamakawa, Takashi Tagami, Yutaka Umemura, Takeshi Wada, Ryo Yamamoto, Hiroki Nagasawa, Wataru Takayama, Masayuki Yagi, Kyosuke Takahashi, Mitsuaki Kojima, Chihiro Narita, Satoshi Kazuma, Jiro Takahashi, Atsushi Shiraishi, Masaki Todani, Masaki Nakane, Toshihiko Nagata, Shohei Tanaka, Yuta Yokokawa, Kunihiko Takahashi, Haruka Ishikita, Ryo Hisamune, Junichi Sasaki, Ken-Ichi Muramatsu, Hiroyuki Sonobe, Kazunobu Minami, Hiromasa Hoshi, Yasuhiro Otomo, OPTPRESS trial investigators
Published in
Intensive care medicine. May 13, 2025. Epub May 13, 2025.
Abstract
We examined the effect of a high-target mean arterial pressure (MAP) on septic shock in a previously underrepresented region.
A multicentre, pragmatic, open-label, randomised controlled trial was conducted in 29 hospitals in Japan, where the prevalence of chronic hypertension among older individuals is 66.9%. Patients who were diagnosed with septic shock, aged ≥ 65 years, and admitted to an intensive care unit were randomised 1:1 to the high (target MAP = 80-85 mmHg) or control (target MAP = 65-70 mmHg) groups from 1 July 2021 to 12 December 2023. The target MAP was maintained for 72 h or until vasopressors were no longer required. The primary outcome was the 90-day all-cause mortality. Secondary outcomes included organ support-free days and adverse events.
The trial was terminated early on the basis of the interim analysis results, suggesting the harm of the high-target strategy. Of the 518 patients, 258 were in the high-target group, and 260 were in the control group. By 90 days after randomisation, 101 patients (39.3%) in the high-target group and 74 (28.6%) in the control group had died from any cause (risk difference = 10.7; 95% confidence interval, 2.6-18.9). Renal replacement therapy-free days at 28 days were shorter in the high-target group. No clinical benefits for any outcome were observed in any subpopulation, including those with known chronic hypertension.
Among older patients with septic shock, high-target MAP significantly increased mortality compared with standard care.
UMIN Clinical Trials Registry; UMIN000041775; 13 September 2020.
PMID:
40358717
Bibliographic data and abstract were imported from PubMed on 13 May 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 292
- Comments 0